Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Pyruvate dehydrogenase complex E2 subunit, also known as dihydrolipoyllysine-residue acetyltransferase (DLAT), is a core enzymatic component of the mitochondrial pyruvate dehydrogenase complex (PDC) (UniProt: P10515). It plays a vital role in aerobic respiration by catalyzing the conversion of pyruvate into acetyl-CoA, effectively linking glycolysis to the tricarboxylic acid (TCA) cycle (PubMed: 23543447). Structurally, the E2 subunit forms the scaffold of the complex and utilizes a lipoic acid cofactor to transfer acetyl groups between active sites. In clinical medicine, PDC-E2 is most recognized as the primary autoantigen in Primary Biliary Cholangitis (PBC), where anti-mitochondrial antibodies (AMA) target this protein, leading to the autoimmune destruction of small bile ducts (PubMed: 28803133). Beyond autoimmunity, DLAT is an emerging target in oncology, as certain cancer cells rely on PDC activity for metabolic flexibility. Drugs like devimistat (CPI-613) inhibit E2 to disrupt mitochondrial metabolism in tumor cells (ClinicalTrials.gov: NCT03504423). Genetic mutations in the DLAT gene can also lead to pyruvate dehydrogenase deficiency, a condition characterized by lactic acidosis and severe neurological dysfunction (NCBI Gene: 1737). Overall, the E2 subunit is a critical metabolic node with significant implications in autoimmune, genetic, and neoplastic diseases.
The E2 subunit catalyzes the transfer of an acetyl group from the lipoyl group of the enzyme to coenzyme A (CoA), producing acetyl-CoA and leaving a reduced dihydrolipoyl group (PubMed: 23543447). This reaction is part of the multi-step oxidative decarboxylation of pyruvate. Drugs like devimistat act by mimicking the lipoate cofactor, leading to the inhibition of the E2 and E3 subunits within the complex (ClinicalTrials.gov: NCT03504423).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex (DLAT).